Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: The invention provides an isolated gene coding for a protein regulating aureobasidin sensitivity; a process for cloning the gene with the use of the gene or a part of the same as a probe; a nucleic acid probe being hybridizable with the gene; an antisense DNA or RNA of the gene; a recombinant or transformant having the gene contained therein; an isolated protein regulating aureobasidin sensitivity and a process for producing the same by using the transformant; an antibody for the protein; a process for detecting the protein or the gene; and a process for screening an antimycotic by using the protein or the transformant. The invention is useful in the diagnosis and treatment of diseases including mycoses.

Abstract: There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.

Abstract: The present invention provides a protein regulating the sensitivity of fungus to an antimycotic aureobasidin, a gene coding for this protein, the use thereof, an antibody for the protein and the use thereof. The invention is useful in the diagnosis and treatment for diseases including mycoses. The invention also provides a novel chromosome integration vector capable of imparting a novel selective marker of a drug resistance to a fungal transformant, a transformant transformed with this vector and a process for producing the same. In particular, it provides a protein capable of imparting the resistance to aureobasidin and acting as a selective marker and a DNA coding for the same.

Abstract: The present invention has its object to provide a noble antifungal substance which is use of as clinical medicine in the therapy of fungal infectious diseases. The present invention is related to an antibiotic TKR459 having the following chemical formula (1) or its pharmacologically acceptable salt.

Abstract: The antibiotic TKR2999 having the physicochemical properties described below and its pharmacologically acceptable salt: (1) FAB-MS m/z 971 [M+H)]+, (2) the molecular formula: C44H78N10O14, and high-resolution FAB-MS m/z 971.5776 [M+H]+, (3) the ultraviolet absorption spectrum in methanol has an end absorption, (4) the infrared absorption spectrum by KBr method shows the major absorption wave numbers at 3320, 2920, 1680, 1540, 1210, 1140, 840, 800, and 720 cm−1, (5) aspartic acid, threonine, serine, glycine, alanine, &bgr;-alanine, and ornithine are detected by the amino acid analysis using ninhydrin reaction, and (6) the solubility is that it is soluble in methanol, and practically insoluble in hexane, chloroform, and water.

Abstract: There can be provided a fungal antigen which is an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed; a process for producing the same; a nucleic acid encoding the fungal antigen; a biologic product containing the fungal antigen; a method of stimulating immunological responses by using the biologic product; a method of suppressing allergic reaction to fungi in a vertebrate; and a method for diagnosing a disease caused by fungi in a vertebrate.

Abstract: The production of IgA is selectively inhibited by orally administering 15-deoxyspergualin or pharmacologically acceptable salts thereof, thus preventing and treating IgA-associated immunological diseases such as IgA nephropathy.

Abstract: The present invention has for its object to provide novel biologically active substances which is of value as a therapeutic agent for fungal infections and immune disorders. This invention is related to a biologically active substance TKR2449 analog(s) which is represented by the following general formula (A); (In the formula, R1, R2 and R3 are the same or differ each other, and each represents hydrogen or an alkyl group of carbon number of 1 to 4. R4 is a linear or branched alkyl or alkenyl group of carbon number of 1 to 8.).

Abstract: The invention is directed to isolated DNAs having nucleic acid sequences which encode proteins which regulate aureobasidin sensitivity. Also disclosed are recombinant plasmids containing the DNAs, transformants containing the plasmids, and methods of producing the proteins.

Abstract: The production of IgA is selectively inhibited by orally administering 15-deoxyspergualin or pharmacologically acceptable salts thereof, thus preventing and treating IgA-associated immunological diseases such as IgA nephropathy.

Abstract: The present invention has its object to provide a noble antifungal substance which is use of as clinical medicine in the therapy of fungal infectious diseases.

Abstract: Antibitic TKR2648 having the following chemical formula (I) or its pharmacologically acceptable salt.

Abstract: The present invention intends to provide a derivative of sphingosine analogue that is able to regulate the functions of sphigolipid, and its pharmaceutical compositions. The present invention is the derivatives of sphingosine analogues represented by the general formula (I) described below. In the formula, R1 and R2, which are the same or different each other, are hydrogen, alkyl groups having 1-4 carbon atoms, or acyl groups having 2-5 carbon atoms. R3 and R4, which are the same or different each other, are hydrogen or hydroxyl groups; or R3 and R4 make up a covalent bond. X1 is —(CH2)n—CO—NH—CH(R5)—R6 or —(CH2)m—O—CO—CH(R7)—R8.

Abstract: The present invention aims to provide a novel sphingosine analogue, which is useful as an intermediate for syntheses of novel lipid derivatives such as sphingolipid derivatives and the like that can regulate the effects of sphingolipid. The present invention relates to a sphingosine analogue represented by the general formula (I) described below. In the formula, as for Q1, Q2 and Q3, Q1 and Q2, which are the same or different each other, are hydrogen, alkyl groups having 1-4 of carbon atoms, acyl groups having 2-5 of carbon atoms, or protecting groups of the amino group, and Q3 is a hydrogen or a protecting group of the hydroxyl group; or Q2 and Q3 make up an isopropylidene group and Q1 is a hydrogen or a protecting group of the amino group. Q4 and Q5, which are the same or different each other, are hydroxyl groups, acyl groups having 2-5 of carbon atoms, —O—Q6, or hydrogen; or Q4 and Q5 make up a covalent bond. Q6 is a protecting group of the hydroxyl group.

Abstract: The invention is directed to isolated DNAs having nucleic acid sequences which encode proteins which regulate aureobasidin sensitivity. Also disclosed are recombinant plasmids containing the DNAs, transformants containing the plasmids, and methods of producing the proteins.

Abstract: The object of the present invention is to provide a novel bioactive substance of value as a therapeutic agent for mycosis, and the like.This invention relates to the bioactive substance TKR1785 of the following general formula (A): ##STR1## (wherein R represents --CH(CH.sub.3).sub.2 or --CH(CH.sub.3)C.sub.2 H.sub.5).

Abstract: This invention offers a promoter derived from a yeast which can be used in a complete nutrient medium and is transcriptionally controllable by a PDR1 gene product. Thus, this invention offers a DNA which is represented by SEQ ID NO:1 in the Sequence Listing or a part thereof and has a promoter activity in yeast; a DNA which can be transcriptionally controllable by a PDR1 gene product and has the above-mentioned promoter activity; and a DNA which is hybridizable to the above-mentioned DNA and has a promoter activity in yeast.

Abstract: A gene associated with sensitivity to the antimycotic agent, aureobasidin A, has been isolated. The gene can be detected in a variety of cell types, and variant forms of the gene have been identified in mutant yeast strains. The proteins encoded by these genes are useful in diagnosing and treating mycoses.

Abstract: The present invention provides a protein regulating the sensitivity of fungus to an antimycotic aureobasidin, a gene coding for this protein, the use thereof, an antibody for the protein and the use thereof. The invention is useful in the diagnosis and treatment for diseases including mycoses.The invention also provides a novel chromosome integration vector capable of imparting a novel selective marker of a drug resistance to a fungal transformant, a transformant transformed with this vector and a process for producing the same. In particular, it provides a protein capable of imparting the resistance to aureobasidin and acting as a selective marker and a DNA coding for the same.